Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...

Jonathan Krinsky, chief market technician at BTIG, joins CNBC's 'The Exchange to discuss his outlook on stocks for 2025, what ...

On Wednesday, Nuvation Bio Inc (NUVB) stock saw a decline, ending the day at $3.01 which represents a decrease of $-0.24 or -7.38% from the prior close of $3.25. The stock opened at $3.32 and touched ...

In a report released today, Ryan Zimmerman from BTIG reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price target of ...

Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...

Vuzix Corp (VUZI) stock saw a modest uptick, ending the day at $4.22 which represents a slight increase of $0.11 or 2.68% from the prior close of $4.11. The stock opened at $4.08 and touched a low of ...

Short seller Hindenburg Research accused Carvana of accounting manipulation and unstable loans. The company denies the ...

The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...

BTIG lowered the firm’s price target on Staar Surgical (STAA) to $39 from $49 and keeps a Buy rating on the shares as part of ...

BTIG analyst Marie Thibault raised the firm’s price target on Boston Scientific (BSX) to $101 from $97 and keeps a Buy rating ...

According to a BTIG strategist, the rally in the index was rejected from the previous support trendline and even though there are still four days left for the Santa Claus rally to deliver gains, there ...